TRMS - Trimeris Inc. $70.63 +0.63 (+2.94)

Trimeris is a biopharmaceutical research and development company that focuses on the discovery and development of therapeutic agents. The company's main product is called T-20, a synthetic peptide that inhibits HIV infection from fusing with host blood cells. Shares of TRMS have been on the rise for almost two years. The stock has come from $5 in 1998 to an all- time high of $75.63 on July 10th. Since then, TRMS has traded as low as $51.38 and as high as $72.25 on Tuesday. We believe that TMRS could be ready to challenge the all-time high of $76.00. We are also hoping for a split announcement with the Company's next earnings release, expected on November 2 before the bell. TMRS has enough shares for a split with 60 million shares authorized, with 15.6 million shares outstanding. Going forward, support is the 5-dma at $68.25 with stronger support at the 10-dma, now up to $67. Resistance is Tuesday's high of $72.25 and then the July 12 high of $74. We are looking for entry points on a bounce off $68.25 or a move above $72.25 on volume of at least 75,000 shares by midday. We plan to set stops at $66 as protection.

Picked on Oct 17th @ $70.63 Change since picked +0.00